Candel Therapeutics Quarterly Cash Flow Statement
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
9.94+0.28 (+2.90%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Candel Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Candel Therapeutics generated -$17.2 million of operating cash flow and spent $69,000 on capital expenditures. That left free cash flow of -$17.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Candel Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -38.91M | -8.86M | -29.50M | -11.27M | -4.80M | 7.38M | -14.07M | -10.65M | -22.24M | -8.22M | -11.10M | -8.44M |
| Net Income growth (YoY) | — | -220.08% | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 200.00K | 149.00K | 163.00K | 200.00K | 200.00K | 245.00K | 245.00K | 200.00K | 200.00K | 251.00K | 249.00K | 200.00K |
| Stock-Based Compensation | 2.86M | 1.45M | 1.29M | 1.16M | 1.05M | 314.00K | 1.24M | 1.18M | 1.84M | 1.04M | 939.00K | 686.00K |
| Change in Working Capital | 5.88M | -2.20M | 2.32M | 424.00K | 2.14M | -1.86M | 500.00K | 1.22M | 425.00K | -1.52M | 985.00K | -291.00K |
| Operating Cash Flow | -17.18M | -18.04M | -10.57M | -10.24M | -8.89M | -8.62M | -5.81M | -6.57M | -6.20M | -8.44M | -7.42M | -8.81M |
| Capital Expenditures | -69.00K | -675.00K | -409.00K | -144.00K | -31.00K | -3.00K | -3.00K | 0 | -6.00K | -7.00K | -47.00K | -103.00K |
| Investing Cash Flow | -69.00K | -675.00K | -409.00K | -117.00K | -31.00K | -3.00K | -3.00K | 0 | -6.00K | -7.00K | -27.00K | -103.00K |
| Financing Cash Flow | 23.98M | 93.81M | 43.90M | -3.37M | 17.44M | -1.87M | 91.91M | 1.68M | 1.95M | -1.25M | -121.00K | 0 |
| Net Change in Cash | 6.73M | 75.10M | 32.92M | -13.72M | 8.52M | -10.49M | 86.10M | -4.90M | -4.26M | -9.70M | -7.57M | -8.91M |
| Free Cash Flow | -17.25M | -18.71M | -10.98M | -10.38M | -8.92M | -8.62M | -5.82M | -6.57M | -6.20M | -8.45M | -7.47M | -8.91M |
This table shows 12 quarterly periods of Candel Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CADL's reporting calendar. What is a cash flow statement?